A federal appeals court on Friday upheld a Delaware judge’s decision that invalidated four patents for Teva Pharmaceutical’s Copaxone, clearing the way for competitors to bring generic versions of the company’s multiple sclerosis drug to market.
The decision, from the U.S. Court of Appeals for the Federal Circuit, affects a contingent of drugmakers in New Jersey and Pennsylvania, which had applied to develop generic alternatives to the thrice-weekly, 40-milligram treatment for relapsing-remitting MS. The firms were represented on appeal by Deanne Maynard of Morrison & Foerster in Washington and Shannon Bloodworth of Perkins Coie, who practices out of Washington and Madison, Wisconsin.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]